➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Moodys
Baxter
Boehringer Ingelheim
Colorcon

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR XALKORI

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Xalkori

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01531361 Sorafenib or Crizotinib and Vemurafenib in Advanced Cancer Recruiting M.D. Anderson Cancer Center Phase 1 2012-02-01 The goal of this clinical research study is to find the highest tolerable dose of the combination of ZelborafTM (vemurafenib) with Nexavar® (sorafenib) or Xalkori® (crizotinib) that can be given to patients with advanced cancer. The safety of these drugs will also be studied. Vemurafenib is designed to block a protein called BRAF V600E inside the cancer cells, which is involved in cancer cell growth. Sorafenib is designed to block the function of important proteins in and outside of cancer cells. These proteins are involved in cancer cells growth and new blood vessel development. Crizotinib is designed to block certain abnormal genes found in cancer cells. This may cause the cancer cells to die.
NCT01548144 Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer Active, not recruiting M.D. Anderson Cancer Center Phase 1 2012-04-01 The goal of this clinical research study is to find the highest tolerable dose of the combination of Xalkori (crizotinib) either with Votrient (pazopanib) or Alimta (pemetrexed) or of the combination of 3 study drugs that can be given to patients with advanced cancer. The safety of these drug combinations will also be studied. Crizotinib is designed to block a protein called ALK, which is involved in cancer cell growth and survival. Pazopanib is designed to block the growth of blood vessels that supply nutrients needed for tumor growth. This may prevent or slow the growth of cancer cells. Pemetrexed is designed to block proteins that may cause tumors to grow.
NCT01597258 Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan) Active, not recruiting Pfizer N/A 2012-05-01 The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.
NCT01712217 A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Active, not recruiting Astex Pharmaceuticals Phase 1/Phase 2 2012-10-01 The purpose of the study is to evaluate safety and efficacy of AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Xalkori

Condition Name

Condition Name for Xalkori
Intervention Trials
Carcinoma, Non-Small-Cell Lung 4
Advanced Cancers 3
Advanced Malignant Solid Neoplasm 3
Hematopoietic and Lymphoid Cell Neoplasm 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Xalkori
Intervention Trials
Carcinoma, Non-Small-Cell Lung 15
Lung Neoplasms 11
Neoplasms 10
Lymphoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Xalkori

Trials by Country

Trials by Country for Xalkori
Location Trials
United States 294
Japan 21
China 13
Italy 8
Canada 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Xalkori
Location Trials
Texas 12
Pennsylvania 12
Michigan 10
North Carolina 9
Missouri 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Xalkori

Clinical Trial Phase

Clinical Trial Phase for Xalkori
Clinical Trial Phase Trials
Phase 4 1
Phase 3 5
Phase 2/Phase 3 1
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Xalkori
Clinical Trial Phase Trials
Recruiting 18
Not yet recruiting 11
Active, not recruiting 9
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Xalkori

Sponsor Name

Sponsor Name for Xalkori
Sponsor Trials
Pfizer 19
National Cancer Institute (NCI) 10
M.D. Anderson Cancer Center 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Xalkori
Sponsor Trials
Industry 33
Other 30
NIH 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Moodys
AstraZeneca
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.